HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

State GMO Labeling Bills Flourish, National Prospects Languish

This article was originally published in The Tan Sheet

Executive Summary

At least 15 states have legislation pending to label genetically engineered food that if passed would create a patchwork of laws that would complicate compliance for supplement and food producers. Many of the bills incorporate lessons learned from the failure of California’s Prop 37.

You may also be interested in...



J&J Settles Class Action For “Misleading” Neutrogena Naturals Claims

The case hinges on claims used to promote Neutrogena Naturals cleansers and moisturizers – specifically, that they are “natural products that contain no petrochemicals,” according to court documents. The consumer plaintiffs say they paid a premium over “comparable products” on the basis of those claims.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Ensuring Leading Position For GSK Consumer Products Touted In Management Shift

GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel